Trastuzumab has proven to be a very effective therapy for HER2-positive breast cancer, but de novo oracquired resistance limits its long-term value. New observations from our laboratory suggest severalhypotheses on the mechanisms of resistance to trastuzumab and other therapies targeting the HER network.First, our results suggest that this resistance might stem from incomplete blockade of the signals generatedfrom the various HER-family dimer pairs in the network input layer. Using a limited number of HER2-overexpressing xenograft models we have found that combined drug therapies designed to more completelyblock these heterodimers can overcome resistance to single agents and are even capable of eradicatingmany of these tumors in mice. Our preclinical models and preliminary patient data also suggest alternativemechanisms for resistance to HER-directed therapy that involve the estrogen receptor in some tumors andthe MUC4 mucins in others.Here we propose a series of preclinical studies and an early phase clinical trial to begin to test thesehypotheses. Specifically we will: 1) Confirm our preliminary data that resistance to single-agent HERtargetedtherapy can be overcome by various combinations of trastuzumab, lapatinib, and pertuzumab,designed to more completely block signaling from the HER network input layer, in a large panel of HER2-amplified breast cancer cell lines, and to identify and establish models resistant to these single andcombined antiHER2 drugs for later studies; 2) Determine using these various preclinical HER2-positivemodels whether upregulation of ER or ER signaling to an alternative survival pathway can be induced byHER blockade as a resistance mechanism, and whether simultaneous targeting of ER and HER2 is thennecessary for optimal treatment; 3) Investigate whether upregulation of MUC4 causes resistance to HERtargetedtherapy in our preclinical in vivo model system, thereby providing a new potential diagnostic andtreatment target to investigate in human samples; 4) Lead a multi-institutional phase 2 neoadjuvant clinicaltrial of lapatinib combined with trastuzumab, with serial tissue sampling to assess molecular mechanisms ofaction and resistance, in order to begin to translate our exciting preclinical findings to patients. This work willfacilitate new strategies to circumvent resistance to HER-targeted therapy for improved patient survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058183-14
Application #
7385520
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
2007-12-01
Project End
2012-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
14
Fiscal Year
2008
Total Cost
$161,961
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications